Devyser Diagnostics AB (publ) announcing the strengthening and expanding of its management team as of February 1, 2024. Michael Uhlin, who has been Devyser?s CSO since the fall of 2023, will join the management team, with responsibility for development/innovation, including bioinformatics, clinical affairs and Devyser Genomic Laboratories, Devyser?s CLIA-certified laboratory. He will report to Devyser?s CEO, Fredrik Alpsten.

Michael Uhlin, who also holds a professorship at Karolinska Institutet, has solid experience in the global life sciences sector, in both academia and industry, where he has held various senior positions. He has long been engaged in translational research and development in areas relevant to Devyser?s activities.